What does Divi’s Laboratories do?
Divi’s Laboratories is a Hyderabad company that makes active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients for drug companies around the world 12. Murali Divi founded it in 1990, and Forbes ranks it among the world’s leading API suppliers 1. About 89% of its FY26 sales were exports 3.
| Fact | Detail |
|---|---|
| Founded | 12 October 1990, as Divi’s Research Centre 10 |
| Headquarters | Hyderabad, Telangana 2 |
| Managing director | Murali Divi 14 |
| CEO | Kiran S. Divi 14 |
| Promoter stake | 51.88%, September 2026 8 |
| FY26 revenue | ₹10,560 crore 621 |
| Market value | About ₹2.69 lakh crore, 5 November 2026 21 |
Who owns Divi’s Laboratories?
The Divi family held 51.88% at the end of September 2026, with no shares pledged 89. Murali Divi’s son Kiran S. Divi and daughter Nilima Prasad Divi each held 20.34% 83. Foreign investors held 20.38% and mutual funds 14.66% 8. See who owns Divi’s.
How did Divi’s Laboratories start?
Murali Divi worked at US research firms and spent about six years as managing director of Cheminor, a Dr Reddy’s company, before founding Divi’s 11. He set up Divi’s Research Centre in 1990 to develop cheaper ways of making known drugs and sell the processes to other companies 4. The company took the name Divi’s Laboratories in 1994 and listed in 2003 410. See Divi’s history.
What does Divi’s make?
In FY26 generic APIs made up 45% of revenue and custom synthesis for large drug companies 55% 3. Its generic APIs include naproxen, dextromethorphan, gabapentin and valsartan, and it makes carotenoids such as beta-carotene and lutein 17. Nutraceutical sales were ₹946 crore in FY26 3. It is building a peptide business and expanding its Kakinada site 312. See products.
Results
For the year to 31 March 2026, revenue from operations rose 13% to ₹10,560 crore and net profit 17% to ₹2,568 crore 6. In April-June 2026 revenue rose 27.8% to ₹3,080 crore and profit 65.5% to ₹902 crore 23. The company is effectively free of debt 21. See finances.
Regulatory and local issues
In March 2017 the US FDA put an import alert on Divi’s Unit 2 in Visakhapatnam, exempting most products; the alert was lifted later that year 13. In December 2020 protests against its Kakinada unit led the Andhra Pradesh government to ask Divi’s to pause work until local concerns were addressed; the minister’s office said the company responded favourably 25. See competitors, leadership and investments.
See also healthcare and all companies.